Improving the Quality of Human LifeOverviewArchemix Corp. is a privately-held biopharmaceutical company based in Cambridge, Massachusetts. The company is leading the development of aptamers as a new class of directed therapeutics for the prevention and treatment of chronic and acute diseases. With their unique properties, aptamers offer an alternative to biologics and small molecules in numerous applications and hold extraordinary potential to address unmet medical needs. We have completed a Phase 1 clinical trial for our most advanced aptamer product candidate, ARC1779, and we commenced a Phase 2 clinical trial of ARC1779 in March 2008 in patients suffering from a rare blood disorder known as thrombotic thrombocytopenic purpura, or TTP. About AptamersAptamers are short, synthetically derived, oligonucleotides that form three-dimensional structures that bind with high specificity and affinity to protein and non-protein targets. As therapeutic agents, aptamers combine the optimal characteristics of both small molecule drugs and biologics without many of the associated disadvantages. Leveraging these unique attributes, Archemix is creating a new paradigm in drug discovery and development. Business StrategyArchemix's business strategy is to build and advance a pipeline of proprietary aptamer products in the core areas of cardiovascular disease, hematology and oncology. In parallel, we have and continue to form collaborations with pharmaceutical companies to develop and commercialize a pipeline of partnered aptamers in these and other therapeutic areas. |
 
Aptamers are oligonucleotides that bind to protein targets with high affinity and specificity |
|
